Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.
But the business case for EKSO's growth is very strong.
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.
But the business case for EKSO's growth is very strong.
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.
But the business case for EKSO's growth is very strong.
EKSO is crushing its rivals and hitting many milestones...
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
On June 2, Ekso Bionics Holdings Inc. (OTC: EKSO) stock dropped 24. 28% -- thanks to an anonymous individual writing under the name "The Pump Stopper" who launched a vicious attack on the stock.
But if you've been in this game long enough, you know what to look for and why stuff like this isn't a big deal in the grand scheme of things.
Here's why you shouldn't be worried...
By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM -
Money Morning’s Chief Investment Strategist Keith Fitz-Gerald first told his readers about the incredible profit opportunity in the human augmentation market in October 2014.
Since then, it has provided some of the fastest-growing stocks on the market. And Fitz-Gerald sees the run continuing for years.
“No matter how many times I review the data or I rearrange the puzzle, this is THE trend of the next decade,” Fitz-Gerald said.
And now, the mainstream media is finally catching up with Fitz-Gerald’s predictions…
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
We've loved EKSO Bionics for some time now. It's revenue has gone up 80% since we first recommended it. Its exports surged 250% in one year.
And Sterne Agee kicked off coverage of the company with a "buy" rating and an initial price target of $1.75 per share.
Here's why EKSO should be your next profit play...
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
The human augmentation market will be worth billions of dollars by 2020. It's growing at a rate of 43.52% a year. And some of our readers are already cashing in.
One of our favorite human augmentation stocks has returned 25% since it was first recommended last fall.
Here are the market’s top companies...
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
Investment risk is part of the trading territory. Anyone offering 100% risk-free investments is lying. Right, Mr. Madoff?
Still, there's one tactic you can use to trade as close to "risk-free" as possible. It's gained our readers 100% returns in the process.
Here's what you need to know...